Catalog No.
DHJ70112
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG4-nd
Clonality
Monoclonal
Target
B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9NZQ7
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BMS-936559, MDX-1105
Clone ID
BMS-936559
PD-1/PD-L1 inhibitors, PMID: 26047524
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab, PMID: 28717238
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis, PMID: 29093678
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy, PMID: 28431010
Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART, PMID: 30682108
Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer, PMID: 27457350
Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies, PMID: 25965369
Harnessing the immune system for the treatment of non-small-cell lung cancer, PMID: 23401435
Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559), PMID: 30747773
Immunotherapy in Lung Cancer: A New Age in Cancer Treatment, PMID: 30539506
The authors reply, PMID: 31415323
Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer, PMID: 23263823
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy, PMID: 24917416
Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors, PMID: 24685885
Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer, PMID: 23714523
Saved From Sepsis: Can Immunotherapy Improve Acute and Postacute Outcomes?, PMID: 30985457
PD-1 and PD-L1 antibodies for melanoma, PMID: 25625924
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy, PMID: 27796306
Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions, PMID: 24892254
Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18 F-FDG PET/CT Imaging in Patients with Advanced Melanoma, PMID: 28360208
Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective, PMID: 29203283
Immune Checkpoint Inhibitor Use in Sepsis: Monitoring Immune Checkpoint Inhibitor Toxicity, PMID: 31415322
Residue-specific binding mechanisms of PD-L1 to its monoclonal antibodies by computational alanine scanning, PMID: 34259259
For research use only. Not for human or drug use.
